Mountain Pacific Partners

Alterra Medical LLC is a medical device company based in Salt Lake City, Utah, established in 2019. The company specializes in the development, commercialization, and distribution of medical devices. It provides consulting services to innovators throughout the product lifecycle, from ideation and feasibility studies to market adoption. Alterra Medical supports its partners with hands-on execution in areas such as channel and distributor management and national group purchasing organization (GPO) contracting. By leveraging a clinically-trained sales team, the company aims to facilitate successful commercialization efforts both in the United States and in key international markets.

Xenocor Inc, based in Salt Lake City, Utah, specializes in designing and developing innovative medical devices, particularly for laparoscopic surgery. The company focuses on single-use, high-definition laparoscopy devices that provide superior imaging quality without the need for a power grid. This design allows for minimally invasive surgical procedures at a lower cost compared to traditional methods. Xenocor's xenoscope medical device enhances the safety and effectiveness of surgeries performed in hospitals, surgery centers, and medical outreach organizations, thereby delivering high value to healthcare providers and patients alike.

Cross Vascular is developing a novel transseptal access system.

1st Source Consulting LLC provides business consulting services. The company offers accounting, funding, management, marketing, manufacturing, human resource and benefits, website support, and legal support services. The company was incorporated in 2019 and is based in Salt Lake City, Utah.

Turner Imaging Systems is a developer of the Smart-C battery-powered mini C-arm. The company develops and markets X-ray imaging systems that give the user the ability to acquire X-ray images wherever and whenever they are needed. The latest product, the SMART-C arm, is a fully-functional mini-C-arm system that is battery operated and hand-transportable, improving the way fluoroscopy is performed. Turner Imaging Systems products expand the reach of X-ray imaging to the under-served and humanitarian efforts around the world.

Layla Wellness is a Canadian company that specializes in the development of an intravaginal fertility monitor ring designed to identify the most fertile days for women. This innovative product tracks cervical fluid, which is crucial for conception, and provides users with advanced notice of their fertile window. By integrating this monitoring ring with a mobile application, Layla Wellness offers a user-friendly solution for women seeking to understand their fertility patterns more effectively.

Healyx Labs, Inc. develops and manufactures a medical device for the implementation of affordable wound healing. It offers Kyron negative pressure wound therapy (NPWT) system, a portable and reusable medical device that is used in healing acute, chronic, and postoperative wounds. Its device is used to treat patients with traumatic, sub acute and dehisced wounds, partial-thickness burns, ulcers, skin flaps, and grafts. Healyx Labs, Inc. was founded in 2015 and is headquartered in Mountain View, California.

Operator of a pharmaceutical company intended to develop new drugs through repositioning. The company focuses on repositioning an already approved and widely used anti-diabetes drug as a medication that slows or stops the progression of calcific aortic valve disease, thus providing the healthcare sector with new technology and medication for a problem that currently has no other remedy.

Alterra Medical LLC is a medical device company based in Salt Lake City, Utah, established in 2019. The company specializes in the development, commercialization, and distribution of medical devices. It provides consulting services to innovators throughout the product lifecycle, from ideation and feasibility studies to market adoption. Alterra Medical supports its partners with hands-on execution in areas such as channel and distributor management and national group purchasing organization (GPO) contracting. By leveraging a clinically-trained sales team, the company aims to facilitate successful commercialization efforts both in the United States and in key international markets.

iVeena Delivery Systems, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, specializing in ophthalmology products. Founded in 2006 by Bala Ambati, the company focuses on developing innovative therapies for various ocular conditions. Its product line includes IVMED-10, IVMED-20, IVMED-80, and IVMED-85, which are aimed at treating post-cataract inflammation and pediatric myopia. Additionally, iVeena is engaged in research and development of novel drug candidates targeting conditions such as macular degeneration, diabetic retinopathy, and glaucoma. The company employs a unique drug delivery platform designed to enhance the ocular bioavailability of medications, facilitating effective treatment for both anterior and posterior segments of the eye. Currently, iVeena has several products in the late pre-clinical and research phases, focusing on advanced therapeutic solutions for ophthalmic diseases.

Decoy Biosystems is a biotechnology company developing a novel and potentially best in class, multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. Decoy is dedicated to enhancing the expanding curative cancer immunology for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for approximately 90 percent of all cancer deaths.

Navigen Inc. is a pharmaceutical discovery and development company based in Salt Lake City, Utah, founded in 2014. The company specializes in drug development using D-peptides, with a focus on various therapeutic areas, including HIV prevention and treatment, cancer immunotherapy, and autoimmune diseases. Notable products include CPT31 for HIV, a D-peptide targeting SIRPα for cancer treatment, and an anti-TNF D-peptide that offers advantages over existing biologics. Navigen has effectively implemented a strategy of sourcing early-stage technologies from academic institutions, advancing these innovations through pre-Investigational New Drug studies with the support of approximately $40 million in non-dilutive funding from grants and collaborations. The company aims to file IND applications for its key programs within the next year.